Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting

Szto, G.; Linnemeier, Thomas J.; Ball, Michael

doi:10.1016/s0002-9149(98)00802-9

Cited by 16 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In some cases, the occurrence of neutropenia can appear after eight weeks from initiation [25,26]. It was reported that the neutropenic effect of ticlopidine had led to fatal outcome in patients with infectious diseases [27,28]. This patient was having mild systemic neutropenia which might be due to the prior use of ticlopidine.…”

Section: Discussionmentioning

confidence: 94%

Acyclovir Induced Acute Kidney Injury In Acute Meningitis Patient: A Case Report Highlights the Concurrence Of AKI Risk Factors And The Neutropenic Effect Of Ticlopidine

Amin¹,

Ibrahim

Sarriff³

2014

iosrphr

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Acyclovir Induced Acute Kidney Injury In Acute Meningitis Patient: A Case Report Highlights the Concurrence Of AKI Risk Factors And The Neutropenic Effect Of Ticlopidine

Amin¹,

Ibrahim

Sarriff³

2014

iosrphr

View full text Add to dashboard Cite

“…11 Fractionated heparin is not an alternative for platelet aggregation inhibitors. Ticlopidine has been withdrawn from the Dutch market because of its association with a higher risk of serious and potentially life-threatening adverse reactions compared with clopidogrel.…”

Section: Discussionmentioning

confidence: 99%

Rapid oral desensitisation procedure in clopidogrel hypersensitivity

Oppedijk

Odekerken²,

Wildt³

et al. 2008

NHJL

View full text Add to dashboard Cite

We describe a patient who developed generalised pruritus with oedema and rash two weeks after she had started taking clopidogrel following coronary stent implantation. In the absence of other likely causative agents, clopidogrel hypersensitivity was probable. She was treated with a rapid oral desensitisation procedure, after which a daily dose of 75 mg clopidogrel was well tolerated. No major adverse events occurred during a follow-up period of eight months. Oral desensitisation in clopidogrel hypersensitivity seems to be a safe method to reduce the risk of coronary stent thrombosis. (Neth Heart J 2008;16:21-3.).

show abstract

“…Drug desensitization is useful for IgE type of allergic reactions when there is no available alternative drug. Although switching to ticlopidine may be an option for patients with an allergy clopidogrel, this drug is associated with a higher risk of serious and potentially life‐threatening adverse reactions, including reversible neutropenia, aplastic anemia, and thrombotic thrombocytopenic purpura [11, 12] compared to clopidogrel. All of the patients who were given ticlopidine developed significant adverse drug reactions, necessitating discontinuation of the drug.…”

Section: Discussionmentioning

confidence: 99%

Clopidogrel (Plavix) desensitization: A case series

Camara

Almeda

2005

Cathet. Cardiovasc. Intervent.

View full text Add to dashboard Cite

Clopidogrel (Plavix) is a thiopyridine that inhibits the ADP-dependent pathway for platelet activation and has been shown in numerous trials to be effective for a wide variety of patients with cardiovascular disease, particularly those who have undergone coronary stent implantation and who present with acute coronary syndromes. Allergic rashes are one of the common side effects of clopidogrel, which leads to its discontinuation. Type I (Gell and Combs classification) allergic reactions to drugs may be amenable to drug desensitization, allowing safe and prolonged use of the drug. This case series describes a protocol for clopidogrel desensitization over an 8-hr period using 15 doubling doses of clopidogrel given by mouth to achieve a maintenance dose of 75 mg a day. This case series suggests that patients who have had type I drug allergy to clopidogrel may be rapidly desensitized using this protocol. Further studies enrolling a larger number of patients are indicated to confirm the safety and efficacy of this regimen.

show abstract

Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting

Cited by 16 publications

References 5 publications

Acyclovir Induced Acute Kidney Injury In Acute Meningitis Patient: A Case Report Highlights the Concurrence Of AKI Risk Factors And The Neutropenic Effect Of Ticlopidine

Acyclovir Induced Acute Kidney Injury In Acute Meningitis Patient: A Case Report Highlights the Concurrence Of AKI Risk Factors And The Neutropenic Effect Of Ticlopidine

Rapid oral desensitisation procedure in clopidogrel hypersensitivity

Clopidogrel (Plavix) desensitization: A case series

Contact Info

Product

Resources

About